Predict your next investment

Private Equity
dyeecapital.com

See what CB Insights has to offer

Investments

38

Portfolio Exits

2

About DYEE Capital

DYEE Capital is a private equity & venture capital firm.

DYEE Capital Headquarter Location

Xiamen, Fujian,

China

+86 0592-2518818

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest DYEE Capital News

InventisBio Raises $147M in Series D Financing

Sep 29, 2020

InventisBio , a Shangai, China-based clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, closed a $147m series D financing. The was led by Hillhouse affiliate GL Ventures, followed by Qiming Venture Partners, Janchor, AIHC Capital, Matrix Partner China, Dyee Capital, E Fund Capital and other investors. The existing shareholders including Lilly Asia Venture, OrbiMed Asia, Pudong Innotek, AdvanTech Capital, and CMB International continued their support. Led by Dr. Yaolin Wang, Chairman and CEO, InventisBio is an innovative biotech company that focuses on the research and development of proprietary small molecule drugs for the treatment of cancer and metabolic diseases. Currently, InventisBio has three drug products in the mid- to late-stage clinical development, and one new product just entered global phase I clinical study. Among them, D-0502 is an oral selective estrogen receptor degrader (SERD), which also acts as an estrogen receptor antagonist, with therapeutic potential for the treatment of hormone receptor positive breast cancer. In addition, the company has independently developed a third-generation EGFR-T790M tyrosine kinase inhibitor BPI-D0316 and out-licensed China right to Betta Pharma. This product is currently in registration trials of first- and second-line treatment of EGFR-mutated non-small cell lung cancer patients and the trials are progressing fast. Funds raised in this round will be mainly used to support the company’s current products into phase II clinical studies in China and the United States, including D-0502 trials in hormone receptor positive breast cancer and D-0120 trials in gout. This round will also support the company’s global clinical development of other new drugs, enable further expansion of the company’s product pipeline and team. FinSMEs 29/09/2020

DYEE Capital Investments

38 Investments

DYEE Capital has made 38 investments. Their latest investment was in Zhimeng Biopharma as part of their Series B on November 11, 2021.

CBI Logo

DYEE Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/8/2021

Series B

Zhimeng Biopharma

Yes

1

10/8/2021

Series C - II

Leads Biolab

$100M

Yes

4

8/27/2021

Series C

Recovery Plus

$15.45M

Yes

1

8/23/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

8/23/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/8/2021

10/8/2021

8/27/2021

8/23/2021

8/23/2021

Round

Series B

Series C - II

Series C

Series B

Series A

Company

Zhimeng Biopharma

Leads Biolab

Recovery Plus

Subscribe to see more

Subscribe to see more

Amount

$100M

$15.45M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

4

1

10

10

DYEE Capital Portfolio Exits

2 Portfolio Exits

DYEE Capital has 2 portfolio exits. Their latest portfolio exit was Allist Medicine on December 02, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/2/2020

IPO

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

12/2/2020

00/00/0000

Exit

IPO

Subscribe to see more

Companies

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Sources

2

10

DYEE Capital Team

1 Team Member

DYEE Capital has 1 team member, including current Managing Director, Dezhen Zhu.

Name

Work History

Title

Status

Dezhen Zhu

Managing Director

Current

Name

Dezhen Zhu

Work History

Title

Managing Director

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.